Wall Street brokerages expect Vital Therapies, Inc. (NASDAQ:VTL) to report earnings per share (EPS) of ($0.30) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Vital Therapies’ earnings. The lowest EPS estimate is ($0.31) and the highest is ($0.29). Vital Therapies also posted earnings of ($0.30) per share in the same quarter last year. The business is scheduled to issue its next quarterly earnings report on Thursday, August 3rd.

On average, analysts expect that Vital Therapies will report full-year earnings of ($1.76) per share for the current fiscal year, with EPS estimates ranging from ($2.28) to ($1.25). For the next financial year, analysts forecast that the firm will post earnings of ($1.31) per share, with EPS estimates ranging from ($1.42) to ($1.19). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Vital Therapies.

Vital Therapies (NASDAQ:VTL) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.06. During the same period in the previous year, the firm earned ($0.30) earnings per share.

A number of brokerages have weighed in on VTL. Zacks Investment Research raised Vital Therapies from a “sell” rating to a “hold” rating in a research note on Friday, April 14th. ValuEngine lowered Vital Therapies from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Raymond James Financial, Inc. began coverage on Vital Therapies in a research note on Thursday, May 18th. They set an “outperform” rating and a $6.00 price target on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $8.00.

In other news, Director Muneer A. Satter bought 30,000 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The shares were acquired at an average cost of $3.11 per share, with a total value of $93,300.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Muneer A. Satter bought 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 6th. The stock was purchased at an average cost of $3.19 per share, for a total transaction of $31,900.00. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 108,400 shares of company stock worth $338,153. Corporate insiders own 29.88% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of VTL. Goldman Sachs Group Inc. raised its position in shares of Vital Therapies by 1.8% in the first quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock valued at $258,000 after buying an additional 1,157 shares during the period. Bank of New York Mellon Corp raised its position in Vital Therapies by 11.5% in the first quarter. Bank of New York Mellon Corp now owns 88,104 shares of the company’s stock valued at $352,000 after buying an additional 9,120 shares during the period. SG Americas Securities LLC bought a new position in Vital Therapies during the first quarter valued at approximately $167,000. LMR Partners LLP bought a new position in Vital Therapies during the second quarter valued at approximately $396,000. Finally, UBS Oconnor LLC bought a new position in Vital Therapies during the first quarter valued at approximately $800,000. 26.62% of the stock is currently owned by institutional investors and hedge funds.

Shares of Vital Therapies (NASDAQ:VTL) opened at 2.95 on Friday. Vital Therapies has a 1-year low of $2.25 and a 1-year high of $6.63. The stock’s market capitalization is $124.51 million. The firm has a 50-day moving average price of $2.89 and a 200-day moving average price of $3.71.

TRADEMARK VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/08/04/zacks-analysts-expect-vital-therapies-inc-vtl-to-post-0-31-eps.html.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Get a free copy of the Zacks research report on Vital Therapies (VTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.